Novo Nordisk shares tumbled nearly 10% in European trading on Thursday after the company revealed that its experimental heart disease treatment, ziltivekimab, failed to meet its primary endpoint in a late-stage Phase 3 study.
The negative data from the trial represents a significant blow to the Danish pharmaceutical giant’s efforts to diversify its pipeline beyond its dominant diabetes and obesity franchises.
The sharp sell-off underscores growing investor anxiety regarding the company’s ability to deliver on broader therapeutic ambitions.
While Novo Nordisk remains the market leader in GLP-1 therapies, the failure of ziltivekimab removes a potential avenue for addressing cardiovascular risks associated with metabolic conditions.
The stock’s reaction was immediate and severe, reflecting the high expectations placed on the drug’s potential to expand the company’s addressable market.
This development arrives during a turbulent period for Novo Nordisk’s clinical pipeline.